Inactive Instrument

ProLung, Inc.

Equities

LUNG

US74348P2092

Healthcare Facilities & Services

Prolung, Inc. Reports Earnings Results for the Year Ended December 31, 2019

July 15, 2020 at 04:55 pm EDT

ProLung, Inc. announced earnings results for the year ended December 31, 2019. For the year, the company announced operating loss was USD 3.563 million compared to USD 4.531 million a year ago. Net loss was USD 4.619 million compared to USD 7.709 million a year ago. Basic loss per share from continuing operations was USD 1.19 compared to USD 2 a year ago.

Latest news about ProLung, Inc.

ProLung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
ProLung, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
ProLung, Inc. Auditor Raises 'Going Concern' Doubt	23-04-16	CI
ProLung, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
ProLung, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
ProLung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-23	CI
ProLung, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
ProLung, Inc. Auditor Raises 'Going Concern' Doubt	22-04-14	CI
ProLung, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
IONIQ Sciences, Inc. Announces the Appointment of Aaron B. Dorny to Its Board of Directors	21-10-07	CI
Prolung, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-16	CI
Prolung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-24	CI
Prolung, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-05-03	CI
Prolung, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	21-03-16	CI
ProLung, Inc. announced that it has received $0.182 million in funding	20-12-20	CI
ProLung, Inc. announced a financing transaction	20-12-02	CI
Prolung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-08-25	CI
Prolung, Inc. Reports Earnings Results for the Year Ended December 31, 2019	20-07-15	CI
ProLung, Inc. has Changed its Name to IONIQ Sciences Inc	20-05-28	CI
ProLung, Inc. announced that it has received $3 million in funding	20-05-21	CI
Prolung, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	20-05-08	CI
ProLung, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	20-03-04	CI
Robert W. Raybould Step Down from the Board of ProLung, Inc	19-11-26	CI
ProLung, Inc. Announces Large Clinical Validation Trial Results of 84% Sensitivity and 74% Specificity	19-10-03	CI
ProLung, Inc. Announces the Appointment of Leavitt Partners and Rich Mckeown to its Board of Directors	19-08-12	CI

Chart ProLung, Inc.

Duration

Period

More charts

Company Profile

Prolung, Inc. is a development-stage medical technology company specializing in predictive analytic, early stage lung cancer risk testing, which refer to as the ProLung Test. The Company's ProLung Test is developed to immediately assess the risk of malignancy in lung nodules found in the chest by a Computed Tomography (CT) scan. The Company's Lead Product is ProLung Test, which is designed to evaluate the risk of lung cancer in patients with lung nodules in well-controlled clinical trials. The ProLung Test includes components, such as ProLung System and ProLung Test Kit. ProLung System consists of the probe, scanner, tower, monitor, and keyboard which are all medical grade components. This component is available for sale in English, French, German, Spanish, and Italian versions. ProLung Test Kit includes six diaphoretic electrodes, one probe tip and one moistening sponge.

Sector

Healthcare Facilities & Services

More about the company

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
SONIC HEALTHCARE LIMITED	-18.02%	8.42B
RADNET, INC.	+69.46%	4.35B
DR. LAL PATHLABS LIMITED	+7.88%	2.74B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-56.54%	1.78B
NEOGENOMICS, INC.	-14.28%	1.7B
FLEURY S.A.	-16.69%	1.47B
METROPOLIS HEALTHCARE LIMITED	+17.87%	1.19B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-49.60%	1.03B
ADICON HOLDINGS LIMITED	-21.78%	927M

Medical & Diagnostic Laboratories